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Abstract
Background—Azithromycin has been used to treat primary and secondary syphilis and as
prophylaxis for sexual partners. We evaluated syphilis treatment failure in patients who received
azithromycin therapy.
Methods—Patients who did not respond to azithromycin therapy were referred to Shanghai Skin
Disease and sexually transmitted disease hospital. Treatment failure was defined as follows: (1)
persistent ulcers or cutaneous or mucosal lesions 1 month after therapy; or (2) detection of
spirochetes in dark-field microscopy examination of a lesion at least 1 week after treatment; or (3)
failure of rapid plasma reagin titers to decrease 4-fold at 3 months after treatment.
Results—A total of 132 patients with primary and secondary syphilis who failed azithromycin
therapy were referred to our hospital between January 2001 and October 2008. Of 132 patients, 42
(31.8%) had primary syphilis and 90 (68.2%) had secondary syphilis. Twenty-six patients with
primary syphilis developed multiple lesions or secondary syphilis, or persistent ulcers despite
using azithromycin. The skin or mucosal lesions did not resolve in 37 patients with secondary
syphilis after azithromycin treatment. Ten patients had a positive dark-field examination for
Treponema pallidum (T. pallidum) after treatment. The serum rapid plasma reagin titers studied in
all cases had failed to decrease 4-fold at 3 months after therapy. The doses of azithromycin used
for treatment ranged from 4 to 30 g.
Conclusions—The failure of azithromycin to cure a substantial number of patients with primary
and secondary syphilis in Shanghai suggests that azithromycin has limited therapeutic value in this
setting.
Syphilis is increasing in China. In 2008, 278,215 cases of syphilis were reported, including
138,667 cases of primary and secondary syphilis, with an incidence of 21.06 cases per
100,000 population. The situation of syphilis is of particular concern in Shanghai, where, in
2008, the incidence of syphilis reached its highest level of 76.78 cases per 100,000
population, the second in the nation. 14,266 cases were reported and 9073 cases were
diagnosed as primary and secondary syphilis.1
Prompt detection of infection and effective treatment are key elements to the control of
syphilis. Penicillin has remained the recommended treatment for syphilis since its discovery
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more than 60 years ago. But penicillin requires special storage conditions and intramuscular
or intravenous delivery, and can cause severe allergic reactions. Accordingly, a safe and
simple alternative therapy has been sought, especially in resources constrained countries.
Azithromycin is an azalide (macrolide) antimicrobial agent with a long half-life (68 hours),
good tissue penetration, and excellent activity against Gram-negative organisms.2–3 It has
been successfully used as a single-dose, oral treatment for early syphilis.4 –9 However, a
Treponema pallidum (T. pallidum) genotype consistent with macrolide resistance has been
described in some patients with treatment failure, especially in patients with concomitant




Between January 2001 and October 2008, sexually transmitted infection (STI) patients with
primary or secondary syphilis were referred to our hospital and evaluated at our public STI
clinic. These patients were originally treated with azithromycin because of allergy to
penicillin or the shortage of penicillin, and they were believed to be potential azithromycin
treatment failures. Patients with persistent high risk unprotected sex following syphilis
treatment were excluded to reduce the possibility of reinfection. All the patients were
evaluated by a physician and treated according to national Chinese STI treatment
guidelines.17 Charts were reviewed to acquire demographic, clinical, and behavioral
information. Clinical laboratory tests were also conducted, including initial dark-field
microscopy, HIV, rapid plasma reagin (RPR) and T. pallidum hemagglutination (TPHA) test
or fluorescent treponemal antibody absorption (FTA-ABS) test before and after
azithromycin administration.
Evaluation Criteria for Treatment Failure
Azithromycin treatment failure after using minimum 4 g (maximum 2 g/day) of
azithromycin was defined according to at least one of the following criteria: (1) persistent
ulcers or cutaneous or mucosal lesions 1 month after treatment; (2) detection of spirochetes
in a dark-field microscopy examination of a lesion at least 1 weak after treatment; (3) failure
to decrease 4-fold for RPR titers within 3 months after treatment.
Gene Mutation at 23S rRNA Gene of T. pallidum
T. pallidum strains were screened for macrolide-resistance mutation by use of published
methods.12 Briefly, swab samples were collected from primary lesions in 4 patients who had
azithromycin treatment failure. DNA was extracted from swab samples using QIAmp DNA
Mini Kit (QIAGEN, CA) following the manufacturer’s instructions under stringent
polymerase chain reaction (PCR)-clean conditions. Mutant isolates were identified using
restriction enzyme analysis of PCR amplifications. A nested PCR and sequencing procedure
were performed to confirm the gene mutation in T. pallidum DNA.
RESULTS
A total of 132 patients with primary or secondary syphilis were identified as azithromycin
failure (Table 1). All patients had an appropriate response to ceftriaxone, procaine penicillin,
and doxycycline therapy (Table 2). Most patients were male with an average age of 32 years
(Table 3). Among 85 men with syphilis, 11 were MSM (men who have sex with men) and 4
were bisexual. Of the patients, 42 (31.8%) had primary syphilis and 90 (68.2%) had
secondary syphilis. None of the 132 patients had a previous history of syphilis. All patients
were tested for HIV with negative results. Forty-two patients with primary syphilis failed
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azithromycin therapy. Ten patients had a positive dark-field examination for T. pallidum
after treatment. 37 had reactive TPHA or FTA-ABS tests and initial RPR titers ranged from
1:1 to 1:32. Among the 5 patients with negative RPR tests, 3 patients had a reactive TPHA
or FTA-ABS tests and 2 showed negative results. Despite azithromycin therapy, persistent
clinical manifestations were apparent in 26 (61.9%) cases, including evolution from one to
multiple ulcers (Fig. 1), other manifestations of secondary syphilis, and nonhealing ulcer
(Table 1). A2058G mutations were found at 23S rRNA gene of T. pallidum in all 4 cases
(Fig. 2). The initially negative RPR in 5 cases turned positive, and TPHA tests of 2 patients
who were nonreactive turned reactive. The remaining 16 patients had primary lesion
resolution, but RPR titers at the follow-up visit remained within ±1 dilution of the initial
RPR titer or increased ≥2 dilutions 3 months after treatment (Table 1). The serum RPR titers
in 42 primary syphilis cases ranged from 1:4 to 1:64 at their first follow-up visit after
azithromycin treatment.
All 90 patients with secondary syphilis had reactive TPHA or FTA-ABS tests and the initial
RPR titers ranging from 1:8 to 1:256. In 37 patients, skin lesions did not disappear 4 weeks
after azithromycin therapy. Among 53 cases whose skin lesions disappeared, the serum RPR
titers in 12 cases increased ≥2 dilutions within 3 months and the RPR titers in other 41 cases
remained within ±1 dilution of the initial RPR titer (Table 1).
All patients subsequently responded to treatment of procaine penicillin (37 cases),
ceftriaxone (92 cases), or doxycycline (3 cases) both clinically and serologically. The
serological and clinical responses are presented in Table 2. A total of 12 and 9 cases were
lost to follow-up at 1 and 3 months, respectively.
DISCUSSION
Penicillin is the only antibiotic currently recommended for primary and secondary syphilis
in non-penicillin allergic patients, but the storage, intramuscular administration, and the life-
threatening allergic potential of this drug greatly complicates the therapy. The antimicrobial
spectrum and long half life of the azithromycin suggest its usage to treat syphilis. Several
small trials demonstrated successful use of single dose azithromycin for primary and
secondary and early latent syphilis.5– 8 Two large clinical trials in Africa also demonstrated
the efficacy of azithromycin treatment of syphilis.4,9
However, azithromycin treatment failures in syphilis were noted in San Francisco in 2002
among HIV infected men who had sex with men.10 A genotypic mutation (A2058G) that
confers resistance to macrolides and azalides in T. pallidum has been described in isolates
from San Francisco, Seattle, Baltimore, and Dublin (Ireland).11 An extremely high
prevalence of the mutation (88.2%) was found in Dublin, Ireland, and a moderately high
prevalence in US cities (10.5%–21.8%).11 In San Francisco during 2004, azithromycin-
resistant T. pallidum strains represented 56.1% of isolates from all available patients treated
with azithromycin for syphilis, compared to only 4.0% during 2000 –2002 and 40.6% during
2003.12 A recent study in Shanghai found that all isolates obtained from 38 subjects
included a A2058G mutation.13 The same scenario happened to all of the 4 patients in the
current report whose specimens were analyzed for the mutation.
The majority of reported azithromycin failures in developed countries have been among
MSM and those with HIV.10,12 However, in our report, 82.4% of the patients reported only
heterosexual behaviors, and all subjects were HIV negative. Only 19.7% of this group of
patients reported receiving an antibiotic in 6 months before therapy with azithromycin.
Nevertheless, azithromycin treatment failures and T. pallidum resistance have not been
reported in Africa. Most published data on azithromycin therapy for syphilis in developing
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countries have shown generally good results, including those from large trials, although
molecular studies have not been performed in these trials.4,9 However, some other reports
and randomized clinical trials in China showed the failure of azithromycin in treating early
syphilis or the various efficacy, from 55% to 92% at the same period of this study.14,18 –21
These trials also showed the trend of rate increase of azithromycin treatment failure over
time. Therefore, it is urgently needed to fully understand the current treatment situation in
syphilitic patients with azithromycin and to monitor the macrolide resistance and gene
mutation in T. pallidum in China.
This study has several limitations. First, the data lack of information about the percentage of
patients treated with azithromycin during the study period in Shanghai or the whole nation,
although we roughly estimated that the rate was about 0.1% to 5.0% in Shanghai. Second,
the results provide no indication about the percentage of patients successfully treated with
azithromycin. Third, compliance with azithromycin therapy was based on patient history,
which might not be accurate. Fourth, the molecular study for treatment failure was only
conducted in 4 patients.
The data of azithromycin treatment for syphilis and macrolide-resistant T. pallidum are very
limited in China. We conducted a project to assess T. pallidum resistance in Shanghai,
China, during 2007 to 2009, and found that, among 132 samples with T. pallidum, 126 had
gene mutations with a rate around 95.5% (unpublished data). It is widely believed that an
increase of 5% in the prevalence of antibiotic resistance is an indicator to discontinue the
particular antibiotics. Therefore, azithromycin might not be an option in treating syphilis in
Shanghai, and the patients who have received azithromycin treatment must be closely
followed up with clinical and serological evaluation for treatment efficacy.
In conclusion, azithromycin resistance in T. pallidum appears to be highly prevalent in
Shanghai and is responsible for the high rate of treatment failure. Although more studies are
required to fully understand the relationship among the treatment failure, macrolide
resistance, and gene mutation in T. pallidum, we strongly suggest azithromycin should not
be used to treat syphilis in the Shanghai area. Furthermore, until additional data are collected
and further research is done, azithromycin should be used with caution to treat syphilis
elsewhere in China and even East Asia.
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Single chancre evolved to multiple lesions after azithromycin treatment.
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Restriction enzyme analysis of PCR amplifications showed A2058G mutations in the 23S
rRNA gene of T. pallidum from 4 patients’ lesions. Street 14 is mutated strain where the
PCR product of 23S rRNA gene could be digested into 2 bands, whereas wild-type Nichols
strain only shows 1 band.
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TABLE 3
Baseline Characteristics of the Study Population (n = 132)
Characteristics Number (%)
Sex
 Male 85 (64.4)
 Female 47 (35.6)
Age
 18–27 38 (28.8)
 28–37 46 (34.9)
 38–47 29 (22.0)
 48–56 9 (6.8)
Self-reported sexual behaviors
 Only homosexual behaviors 11 (8.3)
 Bisexual behaviors 4 (3.0)
 Only heterosexual behaviors 117 (88.6)
History of macrolide therapy in the last 6 mo
 Yes 26 (19.7)
 No 64 (48.5)
 Not known 42 (31.8)
Syphilis stage (before azithromycin treatment)
 Primary 42 (31.8)
 Secondary 90 (68.2)
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